Daniel O'Day's Insider Trades & SAST Disclosures
Daniel O'Day's most recent trade in Gilead Sciences, Inc. was a trade of 6,416 Common Stock done at an average price of $110.1 . Disclosure was reported to the exchange on May 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Daniel O'Day.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.11 per share. | 30 May 2025 | 6,416 | 623,852 (0%) | 0% | 110.1 | 706,497 | Common Stock |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 110.96 per share. | 30 May 2025 | 3,584 | 620,268 (0%) | 0% | 111.0 | 397,696 | Common Stock |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 169,690 | 169,690 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 38,395 | 119,348 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 80,953 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 24,024 | 641,900 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 11,632 | 630,268 (0%) | 0% | 117.2 | 1,363,387 | Common Stock |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 164,473 | 726,032 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.99 per share. | 04 Feb 2025 | 108,156 | 617,876 (0%) | 0% | 98.0 | 10,598,206 | Common Stock |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 60,031 | 561,559 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 506,290 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 10,295 | 104,977 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 4,762 | 501,528 (0%) | 0% | 92.3 | 439,723 | Common Stock |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 500,744 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,295 | 115,272 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 4,749 | 495,995 (0%) | 0% | 81.4 | 386,759 | Common Stock |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 125,567 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 10,295 | 495,142 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel P. O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 4,693 | 490,449 (0%) | 0% | 65.2 | 306,218 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 279,130 | 279,130 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 54,910 | 135,862 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 19,140 | 80,952 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 19,140 | 498,629 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.12 per share. | 10 Mar 2024 | 13,782 | 484,847 (0%) | 0% | 75.1 | 1,035,304 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 10,800 | 479,489 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 10,800 | 100,092 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 179,877 | 548,024 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.26 per share. | 31 Jan 2024 | 79,335 | 468,689 (0%) | 0% | 78.3 | 6,208,757 | Common Stock |
| Gilead Sciences, Inc. | O'Day Daniel | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 50,870 | 368,147 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | O'Day Daniel | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 7,347 | 391,032 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 7,347 | 110,892 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.02 per share. | 10 Dec 2023 | 3,341 | 387,691 (0%) | 0% | 79.0 | 264,006 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 7,346 | 125,587 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 7,346 | 269,534 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.12 per share. | 10 Jun 2023 | 3,409 | 266,125 (0%) | 0% | 78.1 | 266,311 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 215,095 | 215,095 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 47,170 | 132,933 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 19,488 | 96,563 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 19,488 | 378,983 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.50 per share. | 10 Mar 2023 | 14,017 | 375,766 (0%) | 0% | 79.5 | 1,114,352 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 10,800 | 389,783 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 10,800 | 85,763 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 11,362 | 116,051 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 11,362 | 364,337 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.59 per share. | 01 Mar 2023 | 4,842 | 359,495 (0%) | 0% | 79.6 | 385,375 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 136,647 | 412,053 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 78,370 | 275,406 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.02 per share. | 24 Jan 2023 | 59,078 | 352,975 (0%) | 0% | 84.0 | 4,963,734 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 3,300 | 127,413 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 3,300 | 256,178 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.97 per share. | 10 Dec 2022 | 1,542 | 254,636 (0%) | 0% | 88.0 | 135,650 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2022 | 3,301 | 254,406 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2022 | 3,301 | 130,713 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.28 per share. | 10 Sep 2022 | 1,528 | 252,878 (0%) | 0% | 65.3 | 99,748 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 3,300 | 134,014 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 3,300 | 252,644 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.74 per share. | 10 Jun 2022 | 1,539 | 251,105 (0%) | 0% | 60.7 | 93,479 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 399,235 | 399,235 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 64,745 | 137,314 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 13,203 | 72,569 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 13,203 | 260,396 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.92 per share. | 10 Mar 2022 | 11,052 | 249,344 (0%) | 0% | 57.9 | 640,132 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 10,800 | 247,193 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 10,800 | 85,772 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 42,922 | 259,638 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 42,922 | 96,572 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.26 per share. | 01 Mar 2022 | 23,245 | 236,393 (0%) | 0% | 60.3 | 1,400,744 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,362 | 139,494 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 11,362 | 216,716 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 307,355 | 307,355 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 52,810 | 161,656 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 10,800 | 147,136 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 10,800 | 150,856 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.91 per share. | 10 Mar 2021 | 5,123 | 142,013 (0%) | 0% | 63.9 | 327,411 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 42,923 | 149,593 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 42,923 | 120,209 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.46 per share. | 01 Mar 2021 | 24,620 | 136,336 (0%) | 0% | 62.5 | 1,537,765 | Common Stock |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 11,363 | 108,846 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 11,363 | 160,956 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Daniel O'Day | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 59,100 | 106,670 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges